{
  "schema_version": "5.0",
  "artifact_kind": "company_profile",
  "language": "zh-CN",
  "generated_on": "2026-11-09",
  "research_as_of": "2026-11-09",
  "input_context": {
    "name_zh": "药明康德",
    "name_en": "WuXi AppTec",
    "industry_level1": "医药健康",
    "industry_level2": "",
    "official_website": "www.wuxiapptec.com",
    "company_type": "品牌方",
    "logo_url": "https://cdn.brandfetch.io/domain/www.wuxiapptec.com/w/256/h/256/fallback/lettermark/type/icon?c=1idH6DEOXL4sEn7V6hN"
  },
  "entity": {
    "name_zh": "药明康德",
    "name_en": "WuXi AppTec Co., Ltd.",
    "scope": "无锡药明康德新药开发股份有限公司及其合并子公司。经营业务以现行化学、生物学和测试服务为主；历史终止经营业务仅在对应年度财务中保留。",
    "legal_name_zh": "无锡药明康德新药开发股份有限公司",
    "corporate_website": "https://www.wuxiapptec.com/",
    "source_ids": [
      "S01",
      "S04"
    ]
  },
  "basic_info": [
    {
      "key": "legal_name",
      "label": "法定主体或所属主体",
      "value": "无锡药明康德新药开发股份有限公司",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "founded",
      "label": "成立时间",
      "value": "2000-12",
      "scope": "前身在江苏无锡注册成立",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "headquarters",
      "label": "总部",
      "value": "中国上海市浦东新区",
      "scope": "主要办公地；公司注册地为江苏无锡",
      "source_ids": [
        "S02",
        "S10"
      ]
    },
    {
      "key": "listing",
      "label": "上市情况",
      "value": "上海证券交易所603259；香港联交所02359",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "employees",
      "label": "员工人数",
      "value": 35584,
      "unit": "人",
      "as_of": "2026-06-30",
      "scope": "集团员工总人数",
      "statement_date": "2026-08-04",
      "source_ids": [
        "S02"
      ],
      "display": "35,584人"
    },
    {
      "key": "revenue",
      "label": "营业收入",
      "value": 45456165774.18,
      "unit": "人民币元",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "集团合并营业收入，含持续经营及终止经营业务，经审计",
      "statement_date": "2026-03-24",
      "source_ids": [
        "S01"
      ],
      "display": "454.56亿元人民币"
    },
    {
      "key": "current_year_revenue",
      "label": "今年营业收入",
      "value": 45537430834.54,
      "unit": "人民币元",
      "period": {
        "start": "2026-01-01",
        "end": "2026-09-30",
        "basis": "calendar_year"
      },
      "scope": "集团合并营业收入，未经审计；本期终止经营业务无收入",
      "statement_date": "2026-10-27",
      "source_ids": [
        "S03"
      ],
      "display": "455.37亿元人民币"
    },
    {
      "key": "international_revenue",
      "label": "国际业务收入",
      "value": "-",
      "source_ids": [],
      "display": "-"
    },
    {
      "key": "international_revenue_share",
      "label": "国际收入占比",
      "value": "-",
      "source_ids": [],
      "display": "-"
    },
    {
      "key": "sales_coverage",
      "label": "销售覆盖国家及地区",
      "value": [
        "美国",
        "日本"
      ],
      "scope": "已核实客户收入或实际供货目的地的部分国家",
      "source_ids": [
        "S01",
        "S11"
      ],
      "display": "美国、日本"
    }
  ],
  "overview": {
    "paragraphs": [
      {
        "text": "药明康德是一家为制药、生物科技和生命科学机构提供合同研究、开发及生产服务的企业，总部主要办公地位于上海。其一体化CRDMO模式连接药物发现、工艺开发、临床用药与商业化生产，客户可按项目阶段采购单项能力，也可使用跨阶段的整合交付。",
        "source_ids": [
          "S04",
          "S05",
          "S10"
        ]
      },
      {
        "text": "现行业务围绕化学、生物学与测试组织。化学平台包含小分子、寡核苷酸、多肽及相关偶联物，服务对象是拥有药物管线的客户；药明康德的主要角色是研发和生产合作伙伴。集团于2025年出售细胞与基因治疗业务，当前服务范围已随业务组合调整。",
        "source_ids": [
          "S04",
          "S07",
          "S08"
        ]
      }
    ]
  },
  "business": {
    "paragraphs": [
      {
        "text": "小分子业务由研究化学服务与WuXi STA开发制造能力衔接：早期提供合成、药物化学和候选分子优化，后期交付原料药工艺、制剂、分析方法、临床供应及商业生产。合同可以采用全时当量或按服务付费等方式，覆盖不同规模和研发阶段的客户。",
        "source_ids": [
          "S07"
        ]
      },
      {
        "text": "WuXi TIDES为寡核苷酸、多肽与复杂合成偶联物提供端到端服务，包含定制合成、单体和连接子开发、工艺放大、原料药及制剂生产，以及分析、包装和申报支持。平台同时销售核酸及多肽合成用目录原料，让客户既可采购构建单元，也可委托完整开发制造项目。",
        "source_ids": [
          "S08",
          "S09"
        ]
      },
      {
        "text": "生物学服务覆盖靶点发现与验证、筛选、结构生物学、药理模型及转化支持。测试服务则提供药物代谢与药代动力学、安全性评价和生物分析，为候选药物选择、临床试验申请及后续开发形成数据包。生物学与测试能力目前在统一网站展示，并可组合支持同一客户项目。",
        "source_ids": [
          "S06",
          "S05"
        ]
      }
    ],
    "brands": [
      {
        "name": "WuXi AppTec／药明康德",
        "description": "集团主服务品牌；WuXi Chemistry、WuXi Biology、WuXi Testing为业务组织，WuXi STA与WuXi TIDES承担相应专业开发制造及技术平台角色。",
        "source_ids": [
          "S04",
          "S05",
          "S07",
          "S08"
        ],
        "website": "https://www.wuxiapptec.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "医药研发与生产服务"
          }
        ],
        "products": [
          {
            "category": "药物合成原料与构建单元",
            "series": [],
            "representative_products": [
              {
                "name": "2'-O-NMA T amidite（STA-AM10693）",
                "website": null
              },
              {
                "name": "scpBNA MeC(Bz) amidite（STA-LB00001）",
                "website": null
              }
            ],
            "description": "供核酸及多肽合成使用的核苷酸、亚磷酰胺单体、修饰原料和天然/非天然氨基酸衍生物，覆盖发现、开发及商业化生产阶段。",
            "source_ids": [
              "S09"
            ],
            "website": "https://tides.wuxiapptec.com/catalog-product/"
          }
        ],
        "services": [
          {
            "name": "小分子药物研究、开发与生产",
            "description": "向药物研发客户提供合成与药物化学、候选分子优化、原料药工艺、制剂开发、分析、临床供应和商业制造，由RCS与WuXi STA等能力协同交付。",
            "source_ids": [
              "S07"
            ],
            "website": "https://chemistry.wuxiapptec.com/small_molecule"
          },
          {
            "name": "多肽、寡核苷酸及偶联物CRDMO",
            "description": "通过WuXi TIDES向相关药物项目提供发现合成、构建单元与连接子开发、工艺放大、原料药与制剂生产、分析测试、包装标签及监管申报资料支持。",
            "source_ids": [
              "S08"
            ],
            "website": "https://tides.wuxiapptec.com/"
          },
          {
            "name": "药物发现生物学与转化研究",
            "description": "为客户开展靶点验证、筛选、结构生物学、体内外药理与疾病模型研究，支持候选药物选择及临床前向临床的转化。",
            "source_ids": [
              "S06",
              "S05"
            ],
            "website": "https://wuxibiology.com"
          },
          {
            "name": "药物研发测试",
            "description": "提供DMPK、GLP及非GLP安全性评价、生物分析和样本检测，形成服务于临床试验申请及药品开发的研究数据与报告。",
            "source_ids": [
              "S06",
              "S05"
            ],
            "website": "https://www.wuxiapptec.com/services/medical"
          }
        ]
      }
    ],
    "services": []
  },
  "global_presence": {
    "paragraphs": [
      {
        "text": "美国和欧洲是重要客户来源，年报按客户母公司所在地区统计收入；亚洲则同时承担研发与制造任务。瑞士Couvet工厂已有口服固体制剂和包装运营，并向美国、日本及欧洲等目的地供货。2026年新增的商业喷雾干燥平台可与现有制剂生产衔接，德国慕尼黑还提供合格人员及批放行服务。",
        "source_ids": [
          "S01",
          "S11"
        ]
      },
      {
        "text": "公司披露在中国、美国、德国、瑞士、新加坡、日本和韩国开展运营。美国Cranbury、San Diego及Natick有既有实验室或研发服务设施；Middletown新增制造项目仍处于调试与验证阶段，新加坡新基地也在建设中。公司规划Middletown口服固体制剂于2026年第四季度、无菌灌装于2027年投用。",
        "source_ids": [
          "S04",
          "S10",
          "S12"
        ]
      }
    ],
    "market_regions": [
      {
        "region": "亚洲",
        "countries": [
          "日本"
        ],
        "coverage": "partial",
        "source_ids": [
          "S11"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01",
          "S11"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      }
    ],
    "operating_regions": [
      {
        "region": "亚洲",
        "countries": [
          "中国",
          "新加坡",
          "日本",
          "韩国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S02"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "德国",
          "瑞士"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S11"
        ]
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S10"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      }
    ]
  },
  "developments": {
    "window": {
      "start": "2025-11-09",
      "end": "2026-11-09",
      "max_items": 5
    },
    "items": [
      {
        "id": "D01",
        "title": "公布瑞士Couvet商业喷雾干燥设施启用",
        "importance": "major",
        "display_date": "2026-10-13",
        "summary": "药明康德公布在瑞士Couvet制剂基地启用商业级喷雾干燥设施，新增PSD-4设备可制备无定形固体分散体，并与站点既有口服固体制剂、包装及德国批放行服务衔接。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S11"
        ]
      },
      {
        "id": "D02",
        "title": "美国法院就1260H指定给予初步禁令救济",
        "importance": "major",
        "display_date": "2026-08-07",
        "summary": "美国哥伦比亚特区联邦地区法院就药明康德诉国防部一案出具意见，决定初步禁止执行、实施或使药明康德1260H指定发生效力，诉讼仍继续进行。",
        "status": "completed",
        "source_ids": [
          "S13"
        ]
      },
      {
        "id": "D03",
        "title": "美国Middletown基地举行客户预览并披露投产计划",
        "importance": "major",
        "display_date": "2026-06-04",
        "summary": "Middletown基地向客户与合作伙伴开放预览，现场仍在开展设备调试和验证。公司介绍口服固体制剂设施计划2026年第四季度投入运营，无菌灌装能力预计2027年上线。",
        "status": "planned",
        "source_ids": [
          "S12"
        ]
      }
    ]
  },
  "sources": [
    {
      "id": "S01",
      "title": "药明康德2025年年度报告",
      "url": "https://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESH_STOCK/2026/2026-3/2026-03-24/12011363.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-09",
      "published_at": "2026-03-24"
    },
    {
      "id": "S02",
      "title": "药明康德2026年半年度报告",
      "url": "https://static.cninfo.com.cn/finalpage/2026-08-04/1225455027.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-09",
      "published_at": "2026-08-04"
    },
    {
      "id": "S03",
      "title": "药明康德2026年第三季度报告",
      "url": "https://static.cninfo.com.cn/finalpage/2026-10-27/1225624435.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-09",
      "published_at": "2026-10-27"
    },
    {
      "id": "S04",
      "title": "WuXi AppTec官方常见问题",
      "url": "https://www.wuxiapptec.com/about/frequently-asked-questions-about-wuxi-apptec",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S05",
      "title": "WuXi AppTec现行服务目录",
      "url": "https://www.wuxiapptec.com/services",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S06",
      "title": "WuXi Biology and Testing官方服务网站",
      "url": "https://wuxibiology.com",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S07",
      "title": "WuXi Chemistry小分子CRDMO平台",
      "url": "https://chemistry.wuxiapptec.com/small_molecule",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S08",
      "title": "WuXi TIDES端到端CRDMO平台",
      "url": "https://tides.wuxiapptec.com/",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S09",
      "title": "WuXi TIDES目录商品",
      "url": "https://tides.wuxiapptec.com/catalog-product/",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S10",
      "title": "WuXi AppTec全球经营地点",
      "url": "https://www.wuxiapptec.com/about/location",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S11",
      "title": "药明康德公布瑞士Couvet商业喷雾干燥平台启用",
      "url": "https://wxpress.wuxiapptec.com/detail/1084/wuxi-apptec-opens-commercial-scale-spray-drying-manufacturing-platform-at-its-couvet-site-in-switzerland",
      "type": "official_news",
      "accessed_on": "2026-11-09",
      "published_at": "2026-10-13"
    },
    {
      "id": "S12",
      "title": "Middletown工厂预览与全球产能扩张",
      "url": "https://wxpress.wuxiapptec.com/detail/blog/105/build-locally-impact-globally-wuxi-apptec-continues-to-increase-capacity-amid-demand-growth",
      "type": "official_news",
      "accessed_on": "2026-11-09",
      "published_at": "2026-07-15"
    },
    {
      "id": "S13",
      "title": "美国哥伦比亚特区联邦地区法院：药明康德案初步禁令意见",
      "url": "https://www.govinfo.gov/content/pkg/USCOURTS-dcd-1_26-cv-02069/pdf/USCOURTS-dcd-1_26-cv-02069-0.pdf",
      "type": "regulatory",
      "accessed_on": "2026-11-09",
      "published_at": "2026-08-07"
    }
  ],
  "report_template": "core-v4"
}
